Zosano Pharma Reports Second Quarter 2016 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zosano Pharma Reports Second Quarter 2016 Financial Results

FREMONT, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN ), an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the second quarter ended June 30, 2016.

“With the recent announcement of the first subject treated in our M207 pivotal efficacy trial for acute migraine, we remain on track to report data in Q1 2017,” said Dr. Konstantinos Alataris, Zosano’s President and Chief Executive Officer.  “I look forward to providing additional updates as the trial progresses.”  As of August 8, 2016, 196 subjects were enrolled in the trial, 157 of whom were in the run-in phase, 29 subjects were randomized, and 13 of those subjects were treated.

The U.S. Food & Drug Administration (FDA) has indicated that a single, positive, pivotal efficacy study, in addition to a one-year safety study, will be sufficient to file for registration under the 505(b)(2) pathway. The planned pivotal efficacy study is a multicenter, randomized, placebo-controlled trial comparing three doses of M207 (1.0 mg, 1.9 mg, and 3.8 mg) to placebo for the treatment of a single migraine attack. We expect to enroll three hundred and sixty subjects at approximately 35 centers across the United States. The primary endpoints for the study are pain freedom and freedom from most bothersome symptom at two hours post-dosing, which is outlined  in the October 2014 FDA Draft Guidance – “Migraine:  Developing Drugs for Acute Treatment.”

Financial Results for the Second Quarter Ended June 30, 2016

  • Zosano reported a net loss for the second quarter of 2016 of $6.5 million, or $0.54 per share on a basic and diluted basis, compared with a net loss of $7.6 million, or $0.63 per share on a basic and diluted basis, for the same quarter in 2015.
  • Research and development (R&D) expenses for the second quarter of 2016 were $4.3 million, compared with $5.0 million for the same quarter in 2015. The decision to suspend development of product candidates Daily B104 and Weekly B106 (previously known as Daily ZP-PTH and Weekly ZP-PTH, respectively), and D107 (previously known as ZP-Glucagon) in Q1 2016 resulted in an overall decrease in R&D expense compared to the same period last year. This decrease was partially offset by an increase in development expenses related to M207 due to the initiation of our Zotrip pivotal efficacy trial.
  • General and administrative (G&A) expenses for the second quarter of 2016 were $2.0 million, compared with $1.8 million for the same quarter in 2015. The increase in G&A was primarily due to an increase in stock-based compensation costs, and infrastructure and insurance expenses to support our operations as a public company.
  • As of June 30, 2016, we had cash, cash equivalents and marketable securities of $22.9 million, debt of $15.4 million, and 12.0 million common shares outstanding.

About Zosano Pharma

Zosano Pharma Corporation is an emerging CNS company focusing on providing rapid symptom relief to patients using known therapeutics and altering their delivery profile using the Company’s proprietary intracutaneous delivery system. The Company’s goal is to make intracutaneous drug delivery a standard of care for delivering drugs requiring fast onset of action. Zosano Pharma has developed its proprietary intracutaneous delivery system to administer proprietary formulations of existing drugs through the skin for the treatment of a variety of indications.  The Company believes that its intracutaneous delivery system offers rapid and consistent drug delivery combined with ease of use.  The Company is focused on developing products that deliver established molecules with known safety and efficacy profiles for markets where patients remain underserved by existing therapies.  Zosano Pharma anticipates that many of its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com .

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in our 2015 Annual Report on Form 10-K, as filed with the Securities Exchange Commission on March 29, 2016. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

 
ZOSANO PHARMA CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited; in thousands, except per share amounts)
                     
                     
      Three Months Ended June 30,     Six Months Ended June 30,
        2016       2015         2016       2015  
                     
Revenue:                    
License fees revenue     $ -     $ 68       $ -     $ 170  
Collaborative development support services       -       27         -       143  
Total revenue       -       95         -       313  
Operating expenses:                    
Research and development       4,298       5,004         9,920       8,074  
General and administrative       1,951       1,779         4,127       3,078  
Total operating expenses       6,249       6,783         14,047       11,152  
Loss from operations       (6,249 )     (6,688 )       (14,047 )     (10,839 )
Other income (expense):                    
Interest expense, net       (321 )     (441 )       (637 )     (933 )
Other income (expense)       50       (4 )       49       56  
Loss on debt extinguishment       -       (446 )       -       (446 )
Net loss     $ (6,520 )   $ (7,579 )     $ (14,635 )   $ (12,162 )
                     
Net loss per common share  ̶  basic and diluted     $ (0.54 )   $ (0.63 )     $ (1.22 )   $ (1.12 )
                     
Weighted-average shares used in computing net loss per common share  ̶  basic and diluted       12,012       11,942         11,989       10,864  

 

SELECTED CONSOLIDATED BALANCE SHEETS DATA
(in thousands)
           
    June 30,     December 31,
      2016         2015  
    (unaudited)      
Cash, cash equivalents and marketable securities   $ 22,896       $ 36,933  
Total current assets     23,531         37,271  
Total assets     30,660         45,337  
Secured promissory notes, current     6,247         3,360  
Long-term debt     9,109         11,910  
Total liabilities     18,078         18,835  
Stockholders’ equity     12,582         26,502  

Zosano Contact: Konstantinos Alataris, Ph.D. Chief Executive Officer 510-745-1200 Investor Contact: Jamien Jones Blueprint Life Science Group 415-375-3340 x 5 jjones@bplifescience.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Legacy of the Kashi Fair: A Cultural Journey

Updated Category News Views 387

The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...

Continue Reading
Global Forum Focuses on Sustainable Future and Cooperation

Updated Category News Views 260

Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...

Continue Reading
Blue Onion Secures $10 Million to Enhance Financial Data Management

Updated Category News Views 294

Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...

Continue Reading
Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 120

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Investing in Houlihan Lokey: A Decade of Growth Insights

Updated Category News Views 176

Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...

Continue Reading